文献速递心律失常

EFFORTLESS注册研究:皮下植入式心律转复除颤器的植入与中期结局

Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

EFFORTLESS注册研究纳入985例皮下植入式心律转复除颤器(S-ICD)患者,随访3.1±1.5年。30天和360天并发症发生率分别为4.1%和8.4%,1年不适当放电率8.1%,植入时诱发性室速/室颤转复成功率99.5%。该注册研究显示S-ICD达到预设的安全性和有效性终点。

要点

  • S-ICD 360天并发症发生率8.4%,1年不适当放电率8.1%。
  • 植入时诱发性室速/室颤转复成功率99.5%,自发性发作转复成功率97.4%。
  • 1年和5年适当放电率分别为5.8%和13.5%。

核心结论

  • EFFORTLESS注册研究显示S-ICD达到预设的安全性和有效性终点,中期并发症、不适当放电和转复效能与经静脉ICD研究相当。

研究设计与样本

  • EFFORTLESS为全球多中心注册研究,纳入985例S-ICD患者,随访5年,本次报告为全队列随访≥1年的首次分析。

主要发现

  • 患者平均年龄48岁,女性占28%,射血分数43±18%,65%为一级预防适应证,随访3.1±1.5年。
  • S-ICD系统及手术并发症30天发生率为4.1%,360天为8.4%。
  • 1年不适当放电发生率8.1%,随访3.1年后为11.7%。
  • 植入时诱发性室速或室颤转复成功率99.5%,自发性发作转复成功率总体97.4%。
  • 1年和5年适当放电率分别为5.8%和13.5%。

关键数值与推荐

  • 1年并发症率从入组第一四分位至第四分位分别为11.3%、7.8%、6.6%和7.4%,第一四分位与第二至第四分位比较p=0.06。
  • 因需抗心动过速起搏取出装置5例,因需双心室起搏取出4例,因需心动过缓起搏取出1例。

临床怎么用

  • S-ICD可作为避免经静脉导线相关并发症的除颤选择,中期并发症和不适当放电率与经静脉ICD研究相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to defibrillate ventricular arrhythmias, avoiding drawbacks of transvenous leads. The global EFFORTLESS S-ICD (Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD) registry is collecting outcomes in 985 patients during a 5-year follow-up. OBJECTIVES: The primary goal of the EFFORTLESS registry is to determine the safety of the S-ICD by evaluating complications and inappropriate shock rate. METHODS: This is the first report on the full patient cohort and study endpoints with follow-up ≥1 year. The predefined endpoints are 30- and 360-day complications, and shocks for atrial fibrillation or supraventricular tachycardia. RESULTS: Patients were followed for 3.1 ± 1.5 years and 82 completed the study protocol 5-year visit. Average age was 48 years, 28% were women, ejection fraction was 43 ± 18%, and 65% had a primary prevention indication. The S-ICD system and procedure complication rate was 4.1% at 30 days and 8.4% at 360 days. The 1-year complication rate trended toward improvement from the first to last quartile of enrollment (11.3% [quartile 1]) to 7.8% [quartile 2], 6.6% [quartile 3], and 7.4% [quartile 4]; quartile 1 vs. quartiles 2 to 4; p = 0.06). Few device extractions occurred due to need for antitachycardia (n = 5), or biventricular (n = 4) or bradycardia pacing (n = 1). Inappropriate shocks occurred in 8.1% at 1 year and 11.7% after 3.1 years. At implant, 99.5% of patients had a successful conversion of induced ventricular tachycardia or ventricular fibrillation. The 1- and 5-year rates of appropriate shock were 5.8% and 13.5%, respectively. Conversion success for discrete spontaneous episodes was 97.4% overall. CONCLUSIONS: This registry demonstrates that the S-ICD fulfills predefined endpoints for safety and efficacy. Midterm performance rates on complications, inappropriate shocks, and conversion efficacy were comparable to rates observed in transvenous implantable cardioverter-defibrillator studies. (Evaluation oF Factors ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD [The EFFORTLESS S-ICD Registry]; NCT01085435).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Boersma L, Barr C, Knops R, et al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol. 2017. PMID: 28797351. doi:10.1016/j.jacc.2017.06.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。